News >

Novel Radiolabeled ADC Could Improve Outcomes in High-Risk AML

Ariela Katz
Published: Monday, Apr 02, 2018

John Pagel, MD, PhD

John Pagel, MD, PhD
Older patients with active, relapsed, or refractory acute myeloid leukemia (AML) have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy. To address this high-risk population, investigators are pretreating these patients with a novel radiolabeled antibody–drug conjugate, Iomab-B, as part of a stem cell transplantation regimen aimed at improving remission and survival outcomes.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication